Preclinically, ASG-5Me personally has demonstrated powerful antitumor activity, inducing regressions in models of founded prostate, pancreatic and colon cancers.. Seattle and Agensys Genetics initiate ASG-5ME stage I clinical trial for castration-resistant prostate cancer tumor Agensys, Inc., an affiliate of Tokyo-structured Astellas Pharma Inc., and Seattle Genetics, Inc. today announced they have initiated a stage I scientific trial of ASG-5ME for the treatment of castration-resistant prostate malignancy.These results showed the device was: Very reliable Highly accurate Mechanically stable Research continue steadily to validate CyberKnife System's unparalleled tumor targeting capabilities. Highlights include: Two dosimetric research highlight the CyberKnife Program's accuracy. A study undertaken at UT Southwestern INFIRMARY compared the CyberKnife System and linac IMRT programs of sufferers with early-stage larynx cancer. Researchers found the CyberKnife System was better able to reduce the radiation dose on track tissue in high-dose regions. Clinicians can have the confidence to deliver an ablative dosage to the tumor while sparing the immediately adjacent organs at risk. The data demonstrated radiation dose delivery via multiple noncoplanar beams, with the CyberKnife System prospects to unrivaled precision and tissue sparing.